# Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

> **NCT01242514** · PHASE3 · TERMINATED · sponsor: **AstraZeneca** · enrollment: 1917 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** Fostamatinib
- **DRUG:** Fostamatinib
- **DRUG:** Fostamatinib

## Key facts

- **NCT ID:** NCT01242514
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-01
- **Primary completion:** 2015-01
- **Final completion:** 2015-01
- **Target enrollment:** 1917 (ACTUAL)
- **Why stopped:** AZ decision to discontinue fostamatinib development in RA; rights to fostamatinib returned to Rigel Pharmaceuticals.
- **Last updated:** 2014-04-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01242514

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01242514, "Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)". Retrieved via AI Analytics 2026-06-18 from https://api.ai-analytics.org/clinical/NCT01242514. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*